Journal article
The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT).
- Poiani M Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France.
- Labopin M Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France.
- Battipaglia G Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France.
- Beelen DW Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany.
- Tischer J University Hospital of Munich-LMU, Munich, Germany.
- Finke J Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Brecht A Deutsche Klinik fuer Diagnostik, KMT Zentrum, Wiesbaden, Germany.
- Forcade E CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France.
- Ganser A Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
- Passweg JR Hematology, University Hospital Basel, Basel, Switzerland.
- Labussiere-Wallet H Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France.
- Yakoub-Agha I CHU de Lille, LIRIC, INSERM U995, Université de Lille, Lille, France.
- Schäfer-Eckart K Klinikum Nuernberg, Medizinische Klinik, BMT-Unit, Nuernberg, Germany.
- Kroeger N Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Guffroy B Hematology, Hopitaux Universitaires de Strasbourg, France.
- Ruggeri A Ospedale San Raffaele s.r.l., Haematology and BMT, Milan, Italy.
- Esteve J Hospital Clinic, Dept. of Hematology, IDIBAPS, Barcelona, Spain.
- Nagler A EBMT Paris study office, Paris, France.
- Mohty M Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France.
- 2020-09-18
Published in:
- American journal of hematology. - 2020
English
Karyotypic analysis at time of diagnosis has an important value in determining initial response to treatment, remission duration and overall survival (OS) in acute myeloid leukemia (AML). Less is known about its value before allogeneic hematopoietic cell transplantation (allo-HCT) in patients transplanted with active disease, either relapsed or primary refractory (Rel-Ref) AML. We explored the impact of cytogenetic risk (stratification according to MRC-UK) in 2089 patients with either Ref (n = 972) or Rel AML (n = 1117) transplanted during the period 2000-2017. Overall, 154 patients had a favorable risk, 1283 had an intermediate risk and 652 had an adverse cytogenetic risk. Median follow-up was 49 months. Compared to the favorable risk group, intermediate and adverse risk patients were associated with worse leukemia-free survival and OS and also with a higher incidence of relapse. In a subgroup analysis of patients in the intermediate risk group harboring Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD), this remained an important prognostic factor, being associated with worse outcomes. When analyzing patients according to the intensity of the conditioning regimen, no differences were observed for the main transplant outcomes. In conclusion, in patients diagnosed with AML and transplanted with active disease, karyotype remains an important prognostic factor, allowing splitting patients into different risk groups according to their cytogenetics. Similarly, FLT3-ITD mutation also remains a negative prognostic factor in this population.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1002/ajh.26000
- PMID 32944990
- Persistent URL
- https://folia.unifr.ch/global/documents/183373
Statistics
Document views: 10
File downloads: